Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 3/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.51 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7344594 | 1.00 | SLC1A5 (0.55) | SLC1A5KIF11TAAR1GRIK1GRIK2 | |
| SCHEMBL30861851 | 1.00 | SLC1A5 (0.55) | SLC1A5KIF11TAAR1GRIK1GRIK2 | |
| SCHEMBL30963029 | 1.00 | SLC1A5 (0.55) | SLC1A5KIF11TAAR1GRIK1GRIK2 | |
| SCHEMBL20425536 | 1.00 | SLC1A5 (0.55) | SLC1A5KIF11TAAR1GRIK1GRIK2 | |
| SCHEMBL16542492 | 0.91 | GRIK1 (0.52) | SLC1A5KIF11TAAR1GRIK1IDO1 | |
| SCHEMBL430509 | 0.91 | GRIK1 (0.52) | SLC1A5KIF11TAAR1GRIK1IDO1 | |
| SCHEMBL23818056 | 0.84 | SLC1A5 (0.46) | SLC1A5KIF11IDO1TDO2GRIA2 | |
| SCHEMBL18886122 | 0.84 | GRIK1 (0.51) | KIF11GRIK1GRIK2GRIA1GRIA2 | |
| SCHEMBL42994 | 0.83 | SLC7A5 (0.65) | KIF11GRIA2PNMTALPIPKM | |
| SCHEMBL298829 | 0.83 | SLC7A5 (0.65) | KIF11GRIA2PNMTALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628680-A1 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2020-04-01 | — | — | EP | claimed |
| US-10435438-B2 | Modulation of complement activity | RA PHARMACEUTICALS, INC. (US) | 2019-10-08 | — | — | US | claimed |
| US-20190119328-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2019-04-25 | — | — | US | claimed |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | claimed |
| EP-3154561-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA Pharmaceuticals, Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191951-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | MERCK SHARP & DOHME LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4729094-A2 | Modulators of complement activity | UCB Holdings, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12558398-B2 | Inflammatory disease treatment with complement inhibitors | UCB HOLDINGS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4218790-B1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250090624-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12239684-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4028126-B1 | TREATMENT OF A NEUROLOGICAL DISEASE WITH COMPLEMENT INHIBITORS | RA PHARMACEUTICALS INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | disclosed |
| WO-2016123371-A1 | MODULATORS OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160024159-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 | AMGEN INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-0938477-A4 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5952328-A | MAY BE USED TO ALLEVIATE, MEDIATE, REDUCE AND/OR PREVENT DISORDERS WHICH ARE ASSOCIATED WITH ABNORMAL AND/OR ABERRANT ACTIVITY OF CYSTEINE PROTEASES AND/OR SERINE PROTEASES | CEPHALON, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0938477-A1 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1998021186-A1 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119328-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | SLC1A5 4225/4885KIF11 4739/4885TAAR1 4241/4885 |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | SLC1A5 4225/4885KIF11 4739/4885TAAR1 4241/4885 |
| US-20260116923-A1 | CYCLIC PEPTIDE IL-1BETA TRAP FOR THE TREATMENT OF ATHEROSCLEROSIS AND INFLAMMATORY DISORDERS | IL1A, IL1B, IL1RN | SLC1A5 3256/4885KIF11 4831/4885TAAR1 431/4885 |
| US-20250090624-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | SLC1A5 3710/4885KIF11 4658/4885TAAR1 3214/4885 |
| US-10435438-B2 | Modulation of complement activity | C5, C3AR1, CFH | SLC1A5 4225/4885KIF11 4739/4885TAAR1 4241/4885 |
| US-12558398-B2 | Inflammatory disease treatment with complement inhibitors | C5, C1R, SRPRB | SLC1A5 4206/4885KIF11 1922/4885TAAR1 4688/4885 |
| US-12239684-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | SLC1A5 3573/4885KIF11 4610/4885TAAR1 3303/4885 |
| US-20160024159-A1 | POTENT AND SELECTIVE INHIBITORS OF NAV1.7 | SCN7A, SCN9A, SCN1A | SLC1A5 1893/4885KIF11 3091/4885TAAR1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.